Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: (E-SPERANZA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04695704

Recruitment Status : Recruiting

First Posted : January 5, 2021

Last Update Posted : June 3, 2022

See Contacts and Locations

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Institut Català de la Salut

Information provided by (Responsible Party):

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Study Description

Brief Summary:

Recently, a new clinical presentation called "long covid" has been reported, for patients with symptoms lasting for more than 4 weeks from the onset of the disease. Typically, the symptoms comprise dyspnea, cough, headache, arthralgia, fever, abdominal pain, asthenia and skin manifestations This project aims to evaluate the efficacy of Montelukast in improving the quality of life associated with respiratory symptoms in patients with persistent COVID-19 symptoms. The main objective is to compare the efficacy of low-dose Montelukast versus placebo to improve respiratory symptoms in patients with persistent COVID-19 symptoms.

Condition or disease	Intervention/treatment	Phase
Covid19 SARS (Disease)	Drug: Montelukast Other: placebo	Phase 3

Show detailed description

Detailed Description:

In December 2019, the first case of a new coronavirus causing pneumonia was described in Wuhan (China), designated as SARS-CoV-2 by the World Health Organization.

From the start of the SARS-CoV-2 alert until May 21st, 2020, 250,287 cases of coronavirus disease (COVID-19) were reported in Spain. The importance of the COVID-19 pandemic with its high humanitarian and economic cost, urgently requires effective therapies to reduce the severity, complications and mortality associated with this infection.

As the number of cases of COVID-19 increases, so does information regarding the management and evolution of the disease. More recently, a new clinical presentation called "long COVID-19" has been reported, for patients with symptoms lasting for more than 4 weeks from the onset of the disease. Typically, the symptoms comprise dyspnea, cough, headache, arthralgia, fever, abdominal pain, asthenia and skin manifestations.

The inflammatory process produced at the pulmonary and extra pulmonary level, and the immune response triggered have been identified as important mechanisms in the pathophysiology of COVID-19.

Coronavirus infection activates the cytokine cascade at the immune level, in which leukotriene are possibly involved in the development of respiratory symptoms in patients with persistent symptoms after infection by SARS-CoV-2.

Leukotriene antagonists (LTRAs) have a bronchodilator action and inhibit inflammation of the airways, resulting in a significant improvement in asthma symptoms and allergic rhinitis. In asthma, they improve respiratory function, inhalation rate of inhaled β2 agonist, airway inflammation, airway hyper responsiveness, inhaled corticosteroid dosage, and reduce exacerbations.

Regarding the treatment of acute SARS-CoV-2 infection, to date, the available evidence is limited; there are few conclusive clinical trials that allow recommendations based on scientific evidence.

To date, no treatment has been evaluated in long COVID-19. The hypothesis of using Montelukast would be based on the pathophysiological response of the disease mediated by the immune system against the SARS-CoV-2 infection.

Montelukast blocks the action of substances such as leukotriene C4, D4 and E4 by binding to the CysLT1 receptor in the lungs and bronchi. This reduces the bronchoconstriction caused by leukotriene and results in less inflammation.

Montelukast effectively attenuated both lung inflammation induced by Lipopolysaccharides in a mouse model with Acute Respiratory Distress Syndrome, as in human neutrophils.

Individuals affected by long COVID-19 have self-organized to gain visibility. They have made a self-completed form to describe the characteristics of the disease. The "Persistent COVID19" network in Catalonia currently gathers more than 3000 people.

From the contact with the "Persistent COVID19 association" in Catalonia, and in search of a response to this symptomatology, which can be very disabling, a pilot study was carried out in patients with persistent COVID-19 symptoms with off-label use of Montelukast.

Empirical treatment with Montelukast at a dose of 10 mg / day for 14 days was started in 13 patients with long COVID-19, some with symptoms of more than a month of evolution since the beginning of the COVID-19 clinic. The patients were followed up to evaluate the improvement of the symptoms with a numerical scale from 0 to 100 and COPD Assessment Test Scale (CAT), 3 weeks after starting treatment.

An improvement in symptoms was observed a few days after treatment and a good evolution of the sensation of dyspnea, chest pain, symptoms of discomfort, dry cough, and nasal symptoms. Likewise, the incorporation of the patients to their work activity during that period was observed. To date, the improvement continues to exist, without evidence of clinical deterioration.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	284 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	Double-blind randomized placebo-controlled clinical trial,.
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:	Quadruple (Participant, Care Provider, Investigator and Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	Double-blind Randomized Clinical Trial, Placebo-controlled to Assess the Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: E-SPERANZA COVID-19 PROJECT
Actual Study Start Date :	August 1, 2021
Estimated Primary Completion Date :	July 1, 2023
Estimated Study Completion Date :	August 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COVID-19 (Coronavirus Disease 2019)

Drug Information available for: Montelukast

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Montelukast 10mg oral montelukast once daily for 28 days.	Drug: Montelukast 10 mg oral montelukast once daily for 28 days Other Name: antileukotriene
Placebo Comparator: Placebo oral placebo once daily for 28 days.	Other: placebo 10 mg oral placebo once daily for 28 days

Outcome Measures

Primary Outcome Measures :

COP Assessment Test Scale (CAT) [ Time Frame: 7, 14, 21 and 28 days ]
Quality of life of respiratory symptoms according to COPD Assessment Test (CAT The COPD Assessment Test (CAT) is a questionnaire for people with COPD, designed to measure the impact of COPD on a person's life, and how this changes over time.Quality of life of respiratory symptoms according to COPD Assessment Test (CAT). This is a validated self-administered scale to quantify and monitor the impact of COPD on well-being and daily life. It consists of 8 items (from 0 to 5 points), and a total score of 0-40 (0-9 mild, 10-20 moderate, 21-30 severe and 31-40 very severe), being higher scores worse outcome. A difference of 2 or more points in health status is considered clinically significant.

Secondary Outcome Measures :

1min sit-to-stand test [ Time Frame: 14 and 28 days ]
Exercise capacity: number of repetitions performed in the 1min sit-to-stand test
O2 desaturation [ Time Frame: 14 and 28 days ]
O2 desaturation ≥ 4% with effort (1min sit-to-stand test)
Visual Analogical Scale (VAS) [ Time Frame: 7, 14, 21 and 28 days ]
Symptoms evaluated using numeric Visual Analogical Scale (VAS): asthenia, headache, ageusia, anosmia, and rhinitis . It is numbered from 0-10, where 0 is the absence and 10 the greatest intensity, meaning higher scores worse outcome. The patient selects the number that best evaluates the intensity of the symptom.
All-cause mortality [ Time Frame: 7, 14, 21 and 28 days ]
Mortality from any cause during the study
Number of visits to primary care [ Time Frame: 28 days ]
Number of visits of any kind to primary health care settings (phone visit or face to face visit) during the study period.
Number of visits to the emergency room [ Time Frame: 28 days ]
Number of visits to emergency room form primary health o hospital settings during the study period.
Number of hospital admissions. [ Time Frame: 28 days ]
Number of hospital admissions during the study period.
Medication side effects [ Time Frame: 7, 14, 21 and 28 days ]
Number and type of adverse reactions during the study period related to medication.
Days of sick leave [ Time Frame: 28 days ]
Number of days of incapacity for work (sick leave) during the study period.
Factors of inflamatory and prothrombotic processes: D-Dimer, N-terminal prohormone of brain natriuretic peptide (NT Pro-BNP), C-reactive protenin and Antinuclear antibodies (ANA) [ Time Frame: 0 and 28 days ]
To analyze wether the factors of inflamatory and prothrombotic processes (D-Dimer, Pro-BNP, C-reactive protein, and ANA) at the begining of the study are response predictors to the treatment.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients 18 to 80 years old with SARS-CoV-2 infection (positive CRP <10 days from the onset of symptoms) treated in Primary Health Care.
Persistent respiratory symptoms (more than 1 and <12 months of evolution)
Mild-moderate dyspnea: score at the beginning of the study according to the modified Medical Research Council (mMRC) scale from 0 to 3
The patient must be competent to complement the follow-up evaluations.
The patient agrees to participate in the study and take assigned medication during the 4 weeks.
Sign the informed consent

Exclusion Criteria:

Severity criteria: fever> 38ºC, or O2 saturation <93%.
Patients with SARS-Cov-2 pneumonia in the acute / subacute phase.
Patients who have required hospital admission for SARS-Cov-2.
Chronic Obstructive Pulmonary Disease (COPD), asthma, bronchiectasis, pulmonary fibrosis, obstructive sleep apnea syndrome (OSAS), chronic respiratory failure from any cause, home oxygen therapy.
Use of montelukast or zafirlukast ≤ 30 days prior to inclusion
Use of any dose of systemic corticosteroids ≤ 30 days prior to inclusion
Use of gemfibrocil.
Hypersensitivity to montelukast or to any of the excipients included (e.g. lactose.
Any condition (including the inability to swallow pills) that, in the opinion of the researcher, would prevent the completion of taking the medication.
Active malignancy, current or recent chemotherapy treatment (<6 months).
Medical history of infection by the Human Immunodeficiency Virus (HIV) or any serious immunocompromised state.
Pregnancy, planning to get pregnant or patients of childbearing age not undergoing birth control methods.
Breastfeeding mother.
Any other condition for which, in the opinion of the principal investigator, it is considered that the subject does not fit the study.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04695704

Contacts

Layout table for location contacts

Contact: Francisco M Mera Cordero, MD	+34699942492	franmcor@hotmail.com
Contact: Rosa Morros Pedrós, PhD	+34934824124	rmorros@idiapjgol.org

Locations

Layout table for location information

Spain
Primaty health Center Corbera	Recruiting
Corbera De Llobregat, Barcelona, Spain, 08757
Contact: Arnau Segura, MD
Primary Health Center Jaume Soler	Recruiting
Cornellà De Llobregat, Barcelona, Spain, 08940
Contact: Maria Jesus Gallardo, M.D
Primary Health Center 17 Setember	Recruiting
El Prat De Llobregat, Barcelona, Spain, 08820
Contact: Calero Xavier, MD
Primary Health Center Camps Blancs	Recruiting
Sant Boi De Llobregat, Barcelona, Spain, 08830
Contact: Zully Karin Amaya, MD
Primary Health Center Molí Nou	Recruiting
Sant Boi De Llobregat, Barcelona, Spain, 08830
Contact: Marta Via, MD
Primary Health Center Vinyets	Recruiting
Sant Boi De Llobregat, Barcelona, Spain, 08830
Contact: Cristina Armengol, MD
Primary Health Center ElPla	Recruiting
Sant Feliu De Llobregat, Barcelona, Spain, 08980
Contact: Silvia Plaza
Primary Health Center Raval nord	Recruiting
Barcelona, Spain, 08001
Contact: Laura Romera, PiD MD

Sponsors and Collaborators

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Institut Català de la Salut

Investigators

Layout table for investigator information

Study Chair:	Jesus Almeda Ortega, PhD	Institut Català de la Salut
Study Chair:	Sara Bonet Monne, PhD	Institut Català de la Salut
Study Chair:	Betlem Salvador Gonzalez, PhD	Institut Català de la Salut
Principal Investigator:	Francisco Mera Cordero, MD	Institut Català de la Salut

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mera-Cordero F, Bonet-Monne S, Almeda-Ortega J, Garcia-Sangenis A, Cunillera-Puertolas O, Contreras-Martos S, Alvarez-Munoz G, Monfa R, Balanzo-Joue M, Morros R, Salvador-Gonzalez B. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol. Trials. 2022 Jan 6;23(1):19. doi: 10.1186/s13063-021-05951-w. Erratum In: Trials. 2022 Feb 9;23(1):130.

Layout table for additonal information

Responsible Party:	Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
ClinicalTrials.gov Identifier:	NCT04695704
Other Study ID Numbers:	4R21/006
First Posted:	January 5, 2021 Key Record Dates
Last Update Posted:	June 3, 2022
Last Verified:	June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina:


SARS-CoV-2 Montelukast Leukotriene Antagonists Primary Health Care	Clinical Trial Quality of Life Long Term Covid

Additional relevant MeSH terms:

Layout table for MeSH terms

COVID-19 Signs and Symptoms, Respiratory Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases	Respiratory Tract Diseases Montelukast Leukotriene Antagonists Anti-Asthmatic Agents Respiratory System Agents Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Cytochrome P-450 CYP1A2 Inducers Cytochrome P-450 Enzyme Inducers Molecular Mechanisms of Pharmacological Action

To Top